Brodalumab for Moderate-to-Severe Psoriasis: A Comprehensive Review of Efficacy, Safety, and Clinical Positioning.

Abstract

Brodalumab is a monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), offering a novel approach to treating moderate-to-severe psoriasis. By blocking IL-17RA, brodalumab inhibits the activity of multiple pro-inflammatory IL-17 isoforms, including IL-17A, IL-17F, and IL-17C, which are critical in the pathogenesis of psoriasis. This review synthesizes data from Phase I-IV clinical trials and real-world studies to provide a comprehensive overview of brodalumab's efficacy, safety, and clinical role in the treatment of moderate-to-severe psoriasis. Clinical trial data consistently demonstrate its rapid onset of action, high rates of skin clearance, and durability of response. Real-world evidence supports its effectiveness in treatment-resistant cases and among patients with previous biologic failures. Safety considerations include the need for monitoring suicidality, although no causal relationship has been confirmed. Despite being one of the most effective biologic agents available for psoriasis, brodalumab remains underutilized, highlighting the need for improved awareness of its potential clinical advantages. Further research is warranted to better define its role in treatment algorithms and to assess long-term outcomes in broader patient populations.